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TH E P A R A D O X O F MO L E C U L A R I M A G I N G is one that is on the minds of many in the
imaging community today. The promise of agents that would identify local biological processes such as
inflammation, remodeling, angiogenesis, and metabolism is what attracts imaging researchers into this
exciting realm. This excitement is tempered by the reality that there is a long and steep uphill climb to clinical
applicationof anyof these imagingapproaches. This conundrum ishighlighted in this iForumpiece in iJACCbyDrs. Sinusas, Thomas, andMills.Dr. Sinusas highlights the promise of
single-photon emission computed tomogra-
phy (SPECT) and positron emission tomog-
raphy (PET) approaches to imaging of metab-
olism and neuroreceptors, given their high
sensitivity and lower threshold to clinical ap-
plicability as compared with ultrasound and
magnetic resonance imaging approaches. He
also reviews the state of molecular imaging of
atherosclerosis and angiogenesis. He notes that
hybrid imaging of multiple modalities offers sig-
nificant promise for these types of application. He
points out that there are significant barriers to
clinical translation for many of these modalities,
including cost as well as radiation (in the case of the
nuclear techniques and CT).
The piece by Drs. Thomas and Mills pres-
ents more of the day-to-day clinical reality in
regard to molecular imaging. Conventional
imaging as performed in 2011 has already
revolutionized the way diagnoses are made in
clinical cardiovascular medicine. Thus, the
bar is set very high for advances in molecular
diagnostics. In addition, the regulatory (Fed-
eral Drug Administration [FDA]) and reim-
bursement barriers may be so high as to pre-
vent the ultimate clinical application of anyof these novel developments. This is an im-
portant topic for debate, and we are glad to
bring it to our readers.
Molecular Imaging:
In Utilization, on the Horizon,
or in the Distant Future
Albert J. Sinusas, MD
Departments of Medicine and Diagnostic Radi-
ology, Yale University School of Medicine, New
Haven, Connecticut.
THE CONCEPT OF MOLECULAR IMAGING
ORIGINATED WITHIN THE ONCOLOGY
COMMUNITY and has become part of routine
clinical care of patients with cancer, but still
remains primarily on the immediate horizon
for the cardiovascular community. Molecular
imaging is defined as the noninvasive visual-
ization, characterization, and measurement of
biological processes at the molecular and cel-
lular level in humans and other living systems.
Molecular imaging already plays a critical role for
individually tailoring pharmacological and cell-
or genetic-based therapeutic interventions for
cancer, and has become an integral part of clin-
ical trials (1). Therefore, the molecular imaging
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800approach goes beyond providing only
diagnostic and prognostic information
based on the early identification of the
molecular events associated with physi-
ological or pathological processes. The
successful application of a molecular
imaging strategy requires: widespread
education of the medical and lay com-
munities, the availability of appropriate
imaging probes with sufficient sensitiv-
ity and specificity, and imaging in-
struments that enable the visualization
and quantification of these probes with
adequate spatial resolution and accuracy.
This interrogation of the molecular pro-
cesses must be performed in combina-
tion with evaluation of anatomic or
physiological changes. This generally
requires application of multimodality
imaging with fusion of highly sensitive
molecular-targeted approaches with high-
resolution anatomic approaches. To be
clinically applicable, these targeted im-
aging approaches need to complement
or provide incremental value over exist-
ing imaging approaches or measure-
ment of circulating biomarkers. The
goal is to provide a more global view of
a disease process in balance, rather than
focusing on isolated molecular or cellu-
lar events. The topic of cardiovascular
molecular imaging has been previously
reviewed in great detail in a recent re-
view (2). This paper will try to provide
a prospective on how cardiovascular
molecular imaging could play a central
role in day-to-day management of pa-
tients with cardiovascular disease.
Molecular imaging: in current cardiovascular
practice and on the horizon. Two ob-
ious examples of the application of
olecular imaging in clinical cardiovas-
ular medicine include metabolic and
euroreceptor imaging.
METABOLIC IMAGING. The primary
mphasis of metabolic imaging in clinical
ractice has been in the study of myocar-
ial intermediary metabolism, using ei-
her PET or SPECT imaging. fSeveral different radiolabeling strat-
gies have been employed for clinical
ET imaging of metabolism. The most
idely used PET imaging approach is
o radiolabel a substrate analog with
uorine-18 (18F). The best example in
his category is 2-[18F] fluoro-2-deoxy-
D-glucose (FDG). Evaluation of the
myocardial kinetics of FDG provides
an in vivo approach for imaging glucose
uptake by the myocardium, but can also
track myocardial or vascular inflamma-
tion. Several 18F-labeled PET agents
have been proposed for evaluation of fatty
acid metabolism that would have the
potential for widespread metabolic imag-
ing of the heart. These agents have al-
ready entered into clinical trials. The
evaluation of different patterns of myo-
cardial glucose and fatty acid metabolism
with these 18F-labeled agents may have
mportant diagnostic, prognostic, and
herapeutic implications for management
f patients with cardiovascular disease.
Alternatively, naturally occurring
etabolic substrates can be radiola-
eled in specific carbon locations with
arbon-11, such as various fatty acids
1-11C-palmitate or 1-11C-acetate), glu-
ose (1-11C-glucose), and lactate (L-3-11C-
lactate). An advantage of this approach
is that the metabolism of the radiola-
beled substrate is identical to the unla-
beled substrate. With the application of
appropriate mathematical modeling
schemes, the myocardial uptake and
downstream metabolism of these sub-
strates can be assessed in vivo. Disad-
vantages of this approach relate to the
limitation of radiolabeling with 11C,
including the requirement for an onsite
cyclotron and advanced radiochemistry
capabilities. Both of these issues have
significantly limited the widespread
clinical utilization of the 11C PET im-
ging approaches.
SPECT radiolabeled tracers have
lso been utilized to assess myocardial
lucose and fatty acid metabolism, and
ffer practical clinical advantages. One
f the first successful SPECT ap-
roaches for evaluation of oxidative
atty acid metabolism involved the usef 15-(p-iodophenyl)-pentadecanoic
cid (IPPA), which contains an aro-
atic ring at the omega position radio-
abeled with radioiodine. Unfortu-
ately, conventional SPECT imaging
ystems did not have the sensitivity or
emporal resolution to effectively eval-
ate the rapid kinetics of IPPA, and
his approach was never widely applied.
his limitation may disappear with the
ecent introduction of solid-state mul-
idetector SPECT systems that provide
igh sensitivity and the capability for
ynamic “PET-like” imaging.
An alternative solution to the chal-
enges associated with rapid clearance
inetics of IPPA was the develop-
ent of branched-chain analogs of
PPA, such as 123I-beta-methyl-p-
iodophenylpentadecanoic acid (BMIPP).
Alkyl branching inhibited beta-oxidation,
thereby increasing radiotracer retention and
improving SPECT image quality. Kontos
et al. (3) recently reported the results of a
large multicenter clinical trial that applied
BMIPP SPECT imaging for the detec-
tion of acute myocardial ischemia in pa-
tients presenting to the emergency de-
partment with chest pain. This
molecular-based metabolic imaging ap-
proach provided comparable sensitivity to
other imaging approaches, while provid-
ing incremental value in the early detec-
tion of acute coronary syndrome and a
retained performance even after resolution
of symptoms. Thus, metabolic imaging
may offer unique advantages over more
conventional imaging of regional myocar-
dial function or perfusion. The existing
technical limitations of SPECT image
quantification may be overcome with the
availability of hybrid SPECT/CT imag-
ing systems that facilitate correction of
attenuation, scatter, and partial volume
errors, allowing for determination of ab-
solute radiotracer retention. Metabolic
imaging is likely to play an important role
in the evaluation and management of
ischemic myocardial injury, hypertrophic
heart disease, and heart diseases associ-
ated with diabetes and obesity, and com-
plement conventional imaging of perfu-
sion and function.
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801NEURORECEPTOR IMAGING. Another
lassic targeted molecular imaging ap-
roach that has entered multicenter clin-
cal trials involves the imaging of cardiac
euroreceptors in the heart. This work
as primarily focused on in vivo imaging
f sympathetic function in the myocar-
ium. Important alterations in pre- and
ost-synaptic cardiac sympathetic func-
ion occur in several cardiovascular dis-
ases, including ischemic heart disease
nd heart failure, and may be predictive
f risk for sudden cardiac death or death
rom heart failure, as well as for response
o therapeutic interventions. Pre-synaptic
unction can be measured using radiola-
eled norepinephrine analogs such as
11C-meta-hydroxyephedrine (11C-
HED), a PET radiotracer, or 123I-meta-
iodobenzylguanidine (123I-MIBG), a
SPECT radiotracer. Post-synaptic
function can be assessed with 11C-
CGP12177, a radiolabeled beta-
blocker for PET imaging.
Many clinical studies have demon-
strated that 123I-MIBG SPECT imag-
ng provides powerful diagnostic and
rognostic information in patients with
eart failure. In these patients with
eart failure, 123I-MIBG scans typically
show a reduced heart–mediastinum up-
take ratio, heterogeneous distribution
within the myocardium, and increased
123I-MIBG washout from the heart. A
large, prospective, industry-sponsored
trial, the ADMIRE-HF (AdreView
Myocardial Imaging for Risk Evalua-
tion in Heart Failure) study of 123I-
MIBG imaging for risk stratification of
patients with symptomatic heart failure
on contemporary therapy was recently
published (4), and demonstrated a
highly significant relationship between
the time to heart failure–related events
and the heart-to-mediastinal ratio,
which was independent of other com-
monly measured parameters such as left
ventricular ejection fraction (LVEF)
and B-type natriuretic peptide (BNP).
This clinical study also showed a clear
association between severity of myocardial
sympathetic neuronal dysfunction and risk
for subsequent cardiac death (4). OIf the value of cardiac autonomic
assessment using 123I-MIBG or 11C-
ED imaging in combination with
ther conventional or molecular imag-
ng indexes is confirmed, this neurore-
eptor imaging approach may help in
he selection of patients who would
enefit the most from an implantable
ardioverter-defibrillator by means of
dentification of those at increased risk
or potentially fatal arrhythmias, lead-
ng to more cost-effective implementa-
ion of this life-saving device.
Molecular imaging in the future with ex-
panded clinical impact. Molecular im-
aging is moving forward in many other
areas relevant to the cardiovascular sys-
tem. Some of these approaches involve
targeted imaging of critical biological
processes associated with cardiovascular
disease, including inflammation, thrombo-
sis, angiogenesis, apoptosis, necrosis,
fibrosis, atherosclerosis, and remodel-
ing. Figure 1 summarizes the complex
cascade of events associated with the
progression from early to advanced ath-
erosclerosis, ischemic injury, and sub-
sequent post-infarction remodeling,
along with some of the potential mo-
lecular targets for imaging these molec-
ular processes in temporal relation to
conventional imaging approaches that
focus on evaluation of physiology and
changes in anatomic structure. Many
probes targeted at these processes remain
under development, although some have
already reached clinical testing, or have
even completed clinical testing and
have received FDA approval. Several ex-
amples of novel molecular imaging ap-
proaches that have entered clinical testing
are briefly outlined below.
IMAGINGOF ATHEROSCLEROSIS. Ath-
rosclerosis is a chronic inflammatory
isease, and several molecular ap-
roaches targeted at imaging vascular
nflammation have been proposed for
etection of unstable atherosclerotic
laque. Many clinical studies have eval-
ated the potential of 18F-FDG PET
maging of inflammation as an index
or detection of unstable plaque (5).
ther investigators have targeted theroliferation of vascular smooth muscle
ells associated with vascular remodel-
ng. Investigators have also targeted
omponents of the clotting cascade be-
ause plaque rupture or erosion can lead
o activation of circulating platelets and
lotting cascade proteins.
IMAGING OF ANGIOGENESIS. Angio-
genesis is a complex process that in-
volves many cell types and molecular
signals. Potential targets for imaging
of the angiogenic process include tar-
geting endothelial cell markers asso-
ciated with proliferation and/or mi-
gration, inflammatory cell markers,
and markers related to alterations of
the extracellular matrix. Many labo-
ratories, including my own, have been
focused on imaging of integrin acti-
vation as a way to track in vivo the
angiogenic response to ischemic in-
jury or stimulated angiogenesis. We
have also developed and validated
semiautomated quantitative ap-
proaches for accurately estimating in
vivo radiotracer retention in order to
track changes in the angiogenic re-
sponse in relationship to changes in
tissue perfusion. The recent imaging
of v3 integrin by the PET imaging
racer 18F-Galakto-RGD demon-
trates the feasibility of detecting an-
iogenesis in the myocardium in hu-
ans. This molecular imaging
pproach may provide a more sensitive
eans of evaluating angiogenesis and
ptimizing therapy.
IMAGING MYOCARDIAL INFARCTION
AND VENTRICULAR REMODELING.
Evaluation of myocardial infarction
and post-infarct remodeling with im-
aging has traditionally been focused on
evaluation of regional and global ven-
tricular function and changes in global
geometry. Specifically targeting the
molecular events associated with this
complex process may offer substantial
advantages over conventional ap-
proaches that evaluate the gross patho-
physiological changes that occur late in
the process.
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802We have demonstrated that in vivo
targeted SPECT imaging of activation
of matrix metalloproteinases (MMPs)
is feasible, and can provide new un-
derstanding regarding the role that
MMPs play in post-infarct remodel-
ing (6). The application of targeted
MMP SPECT imaging for evalua-
tion of remodeling requires absolute
radiotracer quantification, which is
now possible with hybrid imaging
systems. The rennin-angiotensin sys-
tem is also locally activated during
post-infarct remodeling and contrib-
utes to the progression to heart fail-
ure. In evaluation of the rennin-
angiotensin system, a number of
angiotensin-converting enzyme in-
hibitors and angiotensin 1 antago-
nists have been radiolabeled for mo-
lecular imaging of the heart. These
pre-clinical studies suggest that the im-
aging of the signaling events that take
place within an infarct may be utilized
Figure 1. Role of Molecular Imaging in Ischemic
Illustrated is the complex cascade of molecular and
subsequent angiogenesis, arteriogenesis, and post-
imaging these molecular processes, in temporal rel
tion of physiology and changes in anatomic structu
of the pathophysiological or anatomic changes ass
type 2 adrenergic receptor; LTB4  leukotriene B4;
growth factor receptor.to track critical molecular processes as- asociated with remodeling. To gain a
better understanding of post-infarct re-
modeling, the molecular images will
need to be related to changes in re-
gional mechanics as assessed by con-
ventional imaging approaches. Much
more work is still needed to assess the
feasibility of applying molecular imag-
ing in clinical trials for evaluation of
post-infarction remodeling.
Barriers to clinical translation of molecular
imaging. The lower sensitivity of ultra-
ound or magnetic resonance–based
olecular imaging approaches limits
heir clinical translation. SPECT and
ET imaging approaches provide high
ensitivity, relatively low cost, and a
inimal potential for adverse biological
ffects, and therefore provide the quick-
st means for translation of molecular
maging into patient care. However,
he limited resolution of nuclear imag-
ng requires anatomic colocalization of
uclear images with higher-resolution
rt Disease
lular events associated with the progression from ea
ction remodeling. Highlighted within the green box
n to conventional imaging indexes (blue boxes) usin
Molecular imaging provides a noninvasive evaluation
ted with ischemic heart disease. ACE  angiotensin-c
P  matrix metalloproteinase; VEGF  vascular endonatomic x-ray CT images. The appli- sation of hybrid SPECT-CT and
ET-CT imaging systems will clearly
mprove the quantification of nuclear-
ased molecular imaging approaches,
lthough the advantages of hybrid im-
ging must be weighed against the
otential additive exposure to ionizing
adiation associated with the additional
T imaging. This issue of radiation
xposure is a growing concern within
oth the medical and lay communities.
The utilization of molecular imaging
hould expand with appropriate educa-
ion of the cardiovascular community
nd the increased availability of various
ybrid imaging systems (SPECT-CT,
ET-CT, PET–magnetic resonance
maging) that will facilitate quantifica-
ion of molecular imaging agents.
owever, the current hybrid imaging
ystems have not been optimized for
ardiac applications, and do not provide
dequate correction for cardiac and re-
o advanced atherosclerosis, ischemic injury, and
re some of the potential molecular targets for
andard imaging approaches that focus on evalua-
molecular events that precede the manifestation
erting enzyme; ATII type 2 aR  angiotensin II
lial growth factor; VEGFR  vascular endothelialHea
cel rly t
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803quantification of targeted imaging
agents.
In Defense of Structure,
Function, and Perfusion:
The Case Against
Molecular Imaging
James D. Thomas, MD*
George Mills, MD, MBA†
*Department of Cardiovascular Medi-
cine, Cleveland Clinic, Cleveland, Ohio;
†PAREXEL International Consulting,
Inc., Bethesda, Maryland.
“The future. . . will be exactly like the
past, only far more expensive”
—John Sladek (7)
MOLECULAR IMAGING. THE VERY
ORDS CONJURE UP VISIONS OF
“Bones” McCoy with his medical Tri-
corder scanning a patient (human or
alien) and divining all manner of
diagnoses—past, present, and future.
And how could one not see the future
of medicine in the promise of molec-
ular imaging? Integrin-targeted para-
magnetic nanoparticles identify areas
of vascular injury inapparent in stan-
dard magnetic resonance angiograms.
P-selectin targeted ultrasound micro-
bubbles identify areas of myocardium
hat have suffered as little as 5 min of
schemia hours earlier (8). Radioactive
tracers targeted to MMP hold promise
to identify vulnerable plaques. But be-
fore we get too carried away with these
future wonders of imaging, we should
pause to ponder a few questions. How
many of these techniques are available
today for general clinical use? How
likely is it that a pharmaceutical com-
pany will invest the hundreds of mil-
lions of dollars to push these interesting
but investigational imaging tools
through an uncertain FDA process to
confirm efficacy and safety needed for rapproval and marketing? And, finally,
just how critical is the need for these
investigational agents in current cardiol-
ogy practice? In other words, how lim-
ited are we in current patient care in
cardiology with our current imaging
methodologies? When it comes to ad-
dressing the critical questions in clinical
cardiovascular medicine—structure, func-
tion, and perfusion—current techniques
do an outstanding—and improving—
job. Indeed, it is far more likely that
better diagnoses will result from the
steady evolution of our conventional im-
aging modalities, ultrasound, nuclear car-
diology, and cardiovascular computed to-
mography (CCT), and cardiac magnetic
resonance imaging (CMR), not from the
promised revolutionary changes in molec-
ular imaging.
Despite all its cellular and molecu-
lar intricacies, the assessment of car-
diovascular health involves few con-
cepts outside the realm of a plumber
or auto mechanic: the heart should be
anatomically accurate in its construc-
tion; it should accept blood at low pres-
sure and pump it out at high pressure
through valves that neither leak nor ob-
struct; and it requires a steady delivery
of fuel at rest and, more importantly,
with exercise. In all of these arenas,
contemporary cardiovascular imaging
does an outstanding job.
Cardiovascular anatomy. Consider car-
iovascular anatomy. Simple 2-dimen-
ional echocardiography, available al-
ost anywhere in the world at a cost
nder $8,000, can quickly and reliably
iagnose congenital abnormalities, ven-
ricular dilation, and aortic aneurysms.
ore comprehensive assessment is
ossible with 3-dimensional echocardi-
graphy, now available in single-beat
cquisitions of 90°  90° involving the
rocessing of over 160,000,000 voxels
er second. Even more detailed anat-
my can be discerned with CCT and
MR, which provide isotropic high-
esolution 3-dimensional imaging thile avoiding the pitfalls of poor im-
ging windows that often plague echo-
ardiography (9).
Cardiac function. Perhaps the most
ommon task in cardiovascular imaging
s to assess regional and global ventric-
lar function. Despite all the known
itfalls of the ejection fraction, it is a
imple concept that immediately con-
eys useful information to clinicians in
ny setting. Simple eyeball assessment
f an echocardiogram can quickly char-
cterize left ventricular function as nor-
al or mild, moderate, or severe dys-
unction. A normal resting echocardiogram
uring chest pain virtually rules out acute
schemia as the cause of that chest pain.
eyond this qualitative assessment, new
uantitativemethods are available for echo-
ardiography. By tracking the “speckles”
enerated by interference patterns in the
yocardium, it is possible to derive regional
train, perhaps the purest measure of ven-
ricular contraction. By combining data
rom the 3 standard apical views, one can
enerate a bullet plot that allows one to
ppreciate regional strain patterns at a
lance. Critical parameters of stroke vol-
me and cardiac output can be measured
ither by the difference in end-diastolic and
nd-systolic volumes by 2-dimensional or
-dimensional echo or by use of the conti-
uity equation with pulsed Doppler trac-
ngs or color Doppler from the left ventric-
lar outflow tract. Similar measurements
ith even greater precision can be made
ith CMR and CCT. By placing a grid of
agnetic tagging on the myocardium, it is
ossible to measure regional strain by
MR in a fashion analogous to echo
peckle tracking (10). Equally important to
ystolic function is diastolic function—the
bility of the heart to fill quickly and effi-
iently at low pressure—and here conven-
ional modalities again offer superior assess-
ent to anything proposed by molecular
maging. By carefully combining observa-
ions of transmitral and pulmonary venous
ow, annular motion, and ventricular wall
hickness and left atrial size, it is possible to
iscern the rate of left ventricular filling,
stimate end-diastolic pressure, and charac-
erize diastolic ventricular stiffness. Assess-
). L
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804ment of ventricular torsion provides a
mechanistic link between systole and dias-
tole (11). That these measurements can
be made quickly and repeatedly ex-
plains the widespread integration of
traditional cardiac imaging into heart
failure management.
Coronary artery disease. One of the
most common tasks of a cardiologist is
to assess coronary artery disease: its
detection and assessment of myocardial
ischemia and viability. Despite all the
promise of molecular imaging, the con-
ventional tools we have today are su-
perb for the task. Subclinical athero-
sclerosis can be detected by carotid
ultrasound or magnetic resonance an-
giography; flow-limiting epicardial cor-
onary disease can be assessed with high
sensitivity and specificity by SPECT
perfusion imaging or exercise echocar-
diography. CT angiography provides
compelling evidence of coronary anat-
omy, obstructive lesions, and plaque
characteristics (Fig. 2). Finally, coro-
nary angiography provides the defini-
tive roadmap to guide surgical inter-
vention or provide access for coronary
intervention. The technique is largely
unchanged from the days of Mason
Sones, yet nothing has displaced it after
50 years. But what do we do in the case
of a chronic ischemic cardiomyopathy?
How can we assess the viability of
dysfunctional myocardium to guide the
utility of revascularization? Fortunately
traditional cardiovascular imaging
brings an abundance of tools to this
task. One of the most reliable signs of
myocardial viability is evidence of con-
tractile reserve. For this, inotropic
stimulation (usually with dobutamine)
can be used with echocardiographic or
magnetic resonance imaging to provide
evidence of increased wall thickening.
If a territory improves at low-dose do-
butamine, then degrades at high dose
(the so-called biphasic response), this is
a particularly strong indicator of the
need to revascularize. More sensitive
than contractile reserve is metabolic
viability, evidence that the myocardium
is still maintaining membrane integritydespite little or no mechanical contrac-
tion. Such membrane integrity can be
shown metabolically by positron imag-
ing for FDG uptake. More recently,
delayed CMR imaging of gadolinium
has been shown to be helpful in judging
viability. Where there is gadolinium,
there is scar, and scar will not improve
with revascularization. With coronary
occlusion, necrosis spreads from the
endocardium to the epicardium; so the
more transmural the late gadolinium
enhancement, the less contractile en-
hancement with revascularization.
Thus, for the vast majority of clinical
questions in ischemic heart disease,
contemporary conventional imaging
has the answer.
Other diseases. The same story plays
out again and again for all manner of
cardiovascular diseases. For valvular
heart disease, we need anatomy, quan-
titation of regurgitation and stenosis,
and impact on the ventricle. Echocar-
diography is the mainstay for this, sup-
plemented in some cases by CMR and
CCT. Similarly, pericardial disease is
easily screened for by echo, which can
Figure 2. CT Scan of a Coronary Fistula
Computed tomography (CT) scan showing a ﬁstula
and a persistent left-sided superior vena cava (LSVCreliably diagnose tamponade and guidepericardiocentesis. CCT and CMR
provide detailed anatomic and hemo-
dynamic evidence of constriction. Aor-
tic aneurysm and dissection; pulmonary
embolus and hypertension; congenital
heart disease; cardiac tumors, masses,
thrombi, and other sources of emboli;
thrombotic and atherosclerotic vascular
disease—the list goes on and on. There
simply are few disorders for which
standard imaging cannot suffice.
Guidance of interventions. Finally, con-
ventional cardiovascular imaging has
proven invaluable for guidance of per-
cutaneous and operative interventions.
Intraoperative echo has long been used
to guide valve repair and other proce-
dures. Recently, echocardiographic
guidance has been extended to cathe-
terization and electrophysiology lab
procedures, including percutaneous
aortic valve replacement and mitral
valve repair, closure of atrial and ven-
tricular septal defects and paravalvular
leaks (Fig. 3), and pulmonary vein iso-
lation, among many others. Multimo-
dality imaging is commonly used, such
as when a preoperative CT scan is fused
ow) between the left circumﬂex coronary artery
A  left atrium.(arrwith live 2-dimensional and 3-dimensional
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805transesophageal echocardiography to
improve the safety margin for percuta-
neous aortic valve replacement.
Barriers to molecular imaging. Now, let
s consider the challenges that develop-
ental molecular imaging faces before it
ill move into a significant role in car-
iovascular diagnosis. The vast majority
f agents touted for molecular diagnosis
re investigational and not currently and
enerally available for clinical use. Most
f these new imaging techniques are only
n the early investigational-development
hase, andmany are not even undergoing
ormal controlled clinical trials. And why
ouldn’t commercial imaging and phar-
aceutical companies be actively pursu-
ng all such promising agents? Consider
he development costs and the prolonged
eview process any imaging agent must
ace to achieve regulatory approval. Based
n publically available data, Adrian Nunn
12) has estimated that Schering and
mersham each spent about $150 mil-
ion per year on research and develop-
ent between 1999 and 2004 and yet did
ot get a single new agent or important
ew indication. Even a modest develop-
Figure 3. 3DTEE Guidance of a Mitral Paravalvul
Three-dimensional transesophageal echo (3DTEE) g
leak (arrow). Shown here is a wire passed retrograd
lasso catheter crossing the interatrial septum. StJ ent program is likely to cost in excess of u200 million, with a very uncertain reg-
latory and reimbursement outcome.
“We [FDA] recommend that a med-
cal imaging agent intended for the
ndication diagnostic or therapeutic pa-
ient management be able to improve
atient management decisions. . . or
mprove patient outcomes. . .” (13). The
equirement for patient management
nd outcomes improvement means the
egulatory requirements for approval
as been raised much higher than
hen thallium-201 and Tc99m sesta-
ibi were approved. The FDA has
ade it perfectly clear that simply pro-
ucing a prettier picture of some struc-
ure is not enough to gain approval.
ndeed, the FDA has approved only a
ew new imaging agents in the past 10
ears. And for those agents that do
ake it through the regulatory gaunt-
et, there is a very uncertain reimburse-
ent reward. A general rule of thumb
s that the peak yearly earnings of a
iagnostic or therapeutic agent must
oughly equal its overall development
ost, thus covering the expense of the
any agents that never receive approval
nd to allow investment in future prod-
eak
ng percutaneous closure of a mitral paravalvular
rough the defect, which has been snared by a
Jude’s mitral prosthesis.cts. With the $200 million bench-mark in mind, there is a clear tradeoff
between market size and anticipated
reimbursement. One of the character-
istics of many molecular imaging
agents is focused targeting on very spe-
cific clinical situations, which by neces-
sity are relatively small markets. The
smaller the market, the higher the re-
quired reimbursement (for 100,000
cases/year, reimbursement of $2,000 is
required), which flies in the face of the
prevailing climate of ever smaller reim-
bursement for imaging tests. Just last
year, outpatient nuclear cardiology ex-
ams saw a threat of 36% to 42% cuts in
Medicare reimbursement. Although
these cuts will now be phased in over
time, the long-term trend is clear. For a
new molecular imaging agent to justify
substantially higher costs than existing
agents will require convincing evidence for
improvement in patient care outcomes in
controlled clinical trials, evidence that is
both elusive and extraordinarily expensive
to demonstrate.
Conclusions
The past 40 years have seen stunning
improvements in the ability of noninva-
sive imaging to characterize cardiovas-
cular structure, function, and perfusion.
These strides have come from the pro-
gressive evolution of conventional imag-
ing techniques, with relatively little im-
pact from imaging targeted to specific
molecular moieties. Although the basic
science of molecular imaging continues
to make impressive strides, the regula-
tory and commercial landscape is limit-
ing to these investigational imaging
agents. To continue our impressive
progress in cardiac imaging, we will
need to rely on continuous improve-
ments in our existing techniques, while
we await the magic of a molecular
Tricorder.
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